Biogen Inc (BIIB)

195.92 +2.83 (+1.47%)
Real-time Cboe USD Disclaimer

Biogen Inc Company Profile

Equity Type
Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.
Contact Information
Cambridge,02142 United States
617 679 2000
Top Executives
William A. Hawkins 67 2019 Independent Director
Richard C. Mulligan 66 2009 Independent Director
Brian S. Posner 60 2008 Independent Director
Alexander John Denner 52 2009 Independent Director
William D. Jones 65 2021 Independent Director
Maria C. Freire 67 2021 Independent Director
Nancy L. Leaming 73 2008 Independent Director
Eric K. Rowinsky 64 2010 Independent Director
Caroline D. Dorsa 62 2010 Independent Director
Jesus B. Mantas 52 2019 Independent Director
Michel Vounatsos 59 2016 CEO & Director
Stephen A. Sherwin 72 2010 Independent Director
Stelios Papadopoulos 73 2008 Independent Chairman of the Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles